Other languages Cabaletta Bio, Inc.

Equities

CABA

US12674W1099

Real-time Estimate Cboe BZX Other stock markets 03:17:29 2024-04-29 pm EDT			5-day change	1st Jan Change
10.32 ^USD	-6.31%		-22.07%	-54.27%

Mar. 22	HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating	MT
Mar. 21	Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cabaletta Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21
Cabaletta Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21
Cabaletta Bio Gets Orphan Drug Designation From FDA For Systemic Sclerosis Treatment	Mar. 20
Cabaletta Bio Secures Orphan Drug Designation for Myositis Treatment	Feb. 02
Cabaletta, Inc. Announces FDA Grants Orphan Drug Designation to CABA-201	Feb. 01
Cabaletta Bio Gets Additional FDA Fast Track Labels For CABA-201	Jan. 08
Cabaletta Bio, Inc. Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis	Jan. 08
Sector Update: Health Care Stocks Retreat in Late Afternoon	Nov. 28
Sector Update: Health Care	Nov. 28
FDA Probes T-Cell Malignancies in Patients Receiving CAR-T Cell Therapies	Nov. 28
Cabaletta Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Cabaletta Bio Says US FDA Cleared Generalized Myasthenia Gravis Phase 1/2 Study of CABA-201	Nov. 06
Cellares and Cabaletta Bio, Inc. Partner to Evaluate Automated Manufacturing for CABA-201	Nov. 06
Cabaletta Bio, Inc. Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis	Nov. 06
Cabaletta Bio Insider Sold Shares Worth $146,921, According to a Recent SEC Filing	23-10-20
Cabaletta Bio Gets FDA Clearance For Trial in Systemic Sclerosis	23-10-02
Cabaletta Bio, Inc. Receives U.S. Food and Drug Administration Clearance of Investigational New Drug Application for Treatment of Systemic Sclerosis with CABA-201	23-10-02
Top Midday Gainers	23-09-18
Insider Sell: Cabaletta Bio	23-08-22
Cabaletta Bio, WuXi Advanced Therapies Expand Manufacturing Deal to Include CABA-201	23-08-22

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Cabaletta Bio, Inc.

Equities

CABA

US12674W1099

Other languages

Filters